Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. (ENTA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
enta · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Enanta Pharmaceuticals, Inc. (ENTA) measures how much investors pay for each dollar of the company's trailing earnings. ENTA's current PE ratio of N/A is calculated by dividing its stock price of $11.07 by its TTM earnings per share of -$2.90.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2010 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 10 fiscal years · Front-end computedMinQ1 · 25%23.3x
MedianQ3 · 75%50.4x
Max
At N/A, ENTA's current P/E is lower than in 0% of its annual fiscal year readings over the past 10 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Enanta Pharmaceuticals, Inc.You ENTA | $257M | N/A | — | -$2.90 |
 Assembly Biosciences, Inc. ASMB | $358M | N/A | — | -$0.55 |
 Atea Pharmaceuticals, Inc. AVIR | $346M | N/A | — | -$1.94 |
 Caribou Biosciences, Inc. CRBU | $182M | N/A | — | -$1.59 |
 Foghorn Therapeutics Inc. FHTX | $218M | N/A | — | -$1.18 |
 Immuneering Corporation IMRX | $143M | N/A | — | -$1.27 |
 Nautilus Biotechnology, Inc. NAUT | $296M | N/A | — | -$0.47 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-3.84 | — | |
2024-09-30 FY2024 | — | $-5.48 | — | |
2023-09-30 FY2023 | — | $-6.38 | — | |
2022-09-30 FY2022 | — | $-5.91 | — | |
2021-09-30 FY2021 | — | $-3.92 | — | |
2020-09-30 FY2020 | — | $-1.81 | — | |
2019-09-30 FY2019 | 25.37x | $2.37 | +5.1% | |
2018-09-30 FY2018 | 24.14x | $3.48 | -52.1% | |
2017-09-30 FY2017 | 50.38x | $0.93 | +116.7% | |
2016-09-30 FY2016 | 23.25x | $1.14 | +172.1% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Enanta Pharmaceuticals, Inc. (ENTA) measures how much investors pay for each dollar of the company's trailing earnings. ENTA's current PE ratio of N/A is calculated by dividing its stock price of $11.07 by its TTM earnings per share of -$2.90.
Frequently asked questions
ENTA pe ratio · 6 questionsENTA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $11.07 and TTM EPS of -$2.90. Data sourced from Financial Modeling Prep via ENTA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Enanta Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08